CTXR Citius Pharmaceuticals, Inc.: Earnings per share for the last 12 months

Citius Pharma (CTXR) - corporate logo

Quality control automation in Citius Pharmaceuticals production contrasts with the absence of geopolitical risks due to its operations within the US legal framework. The TTM EPS dynamics reconcile these aspects, where the 57.20 mark serves as a key metric. The business relies on the infection control market, offering the Mino-Lok solution to oncology centers for catheter salvage.

Citius Pharma (CTXR) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/16/2026

CTXR (Citius Pharma): analytical breakdowns and indicator data

Fundamental company valuation:CTXR Citius Pharmaceuticals
Flagship merchandise of Citius Pharmaceuticals Inc.

This indicator measures the trailing twelve-month (TTM) earnings per share (EPS) dynamics, allowing for the elimination of GAAP accounting distortions to assess actual capital inflows. By analyzing comparable annual EPS TTM growth, an investor determines the operational resilience of Citius Pharmaceuticals (CTXR), which is critical when scaling the distribution of specialized catheter solutions within the intensive care and oncology segments.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months